Experienced in Renal Cell Carcinoma (RCC)

Dr. Sapna Patel

Hematology | Oncology
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Renal Cell Carcinoma (RCC)
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sapna Patel is a Hematologist and an Oncologist in Aurora, Colorado. Dr. Patel is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Melanoma, Uveal Melanoma, Metastatic Uveal Melanoma, Melanoma of the Eye, and Tissue Biopsy.

Her clinical research consists of co-authoring 153 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles and participated in 1 clinical trial in the study of Renal Cell Carcinoma (RCC).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
University Of Colorado Hospital Authority
Medical Center Of The Rockies
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

UNIVERSITY PHYSICIANS INCORPORATED
12605 E 16th Ave, Uchealth Anschutz Medical, Aurora, CO 80045

Additional Areas of Focus

Dr. Patel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Enrollment Status: Recruiting
Publish Date: May 13, 2024
Intervention Type: Biological, Drug
Study Drugs: SX-682, Pembrolizumab
Study Phase: Phase 1
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Enrollment Status: Terminated
Publish Date: October 22, 2025
Intervention Type: Biological, Drug
Study Drugs: SD-101, Nivolumab, Ipilimumab
Study Phase: Phase 1
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Drug, Other
Study Phase: Phase 2
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2025
Intervention Type: Drug, Biological
Study Drugs: IN10018, Cobimetinib
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 3
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Biological, Other
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Other, Biological
Study Drug: Peptide Vaccine (LPV7) + Tetanus Peptide
Study Phase: Phase 1/Phase 2
Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous Cd8+ Antigen-Specific T Cells and Anti-Ctla4 for Patients With Metastatic Uveal Melanoma
Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous Cd8+ Antigen-Specific T Cells and Anti-Ctla4 for Patients With Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: January 25, 2024
Intervention Type: Drug, Biological
Study Drugs: Aldesleukin, Autologous CD8+ SLC45A2-Specific T Lymphocytes, Cyclophosphamide, Ipilimumab
Study Phase: Phase 1
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma
Enrollment Status: Unknown
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant
A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant
Enrollment Status: Unknown
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drug: PV-10
Study Phase: Phase 1
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma
Enrollment Status: Completed
Publish Date: August 21, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 15 Less Clinical Trials

153 Total Publications

Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Journal: Cancer discovery
Published: September 17, 2025
Similar Doctors
Distinguished in Renal Cell Carcinoma (RCC)
Dr. Harry A. Drabkin
Oncology | Hematology
Distinguished in Renal Cell Carcinoma (RCC)
Dr. Harry A. Drabkin
Oncology | Hematology

Portercare Adventist Health System

2555 S Downing St 1st Floor, Whcc Wh Cherry Creek, 
Denver, CO 
 (7.9 miles away)
303-316-6677
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Harry Drabkin is an Oncologist and a Hematologist in Denver, Colorado. Dr. Drabkin is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Adult Soft Tissue Sarcoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes. Dr. Drabkin is currently accepting new patients.

Distinguished in Renal Cell Carcinoma (RCC)
Dr. Elizabeth R. Kessler
Oncology
Distinguished in Renal Cell Carcinoma (RCC)
Dr. Elizabeth R. Kessler
Oncology

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
 (0.1 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Kessler is an Oncologist in Aurora, Colorado. Dr. Kessler is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Orchiectomy, and Penectomy. Dr. Kessler is currently accepting new patients.

Distinguished in Renal Cell Carcinoma (RCC)
Dr. Elaine T. Lam
Hematology Oncology | Oncology
Distinguished in Renal Cell Carcinoma (RCC)
Dr. Elaine T. Lam
Hematology Oncology | Oncology

University Physicians Incorporated

12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
 (0.1 miles away)
720-848-0000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elaine Lam is a Hematologist Oncology specialist and an Oncologist in Aurora, Colorado. Dr. Lam is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Renal Cell Carcinoma (RCC). Dr. Lam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile